Capricor Therapeutics, Inc. (CAPR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Capricor Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Capricor Therapeutics, Inc. (CAPR) has returned 5.34% so far this year and 220.34% over the past 12 months. Over the last ten years, CAPR has returned 1.54% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Feb 13, 2007, CAPR's average daily return is +0.32%, while the average monthly return is +7.18%. At this rate, your investment would double in approximately 0.8 years.

Historically, 40% of months were positive and 60% were negative. The best month was Apr 2020 with a return of +483.3%, while the worst month was May 2017 at -73.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, CAPR closed higher 38% of trading days. The best single day was Dec 3, 2025 with a return of +371.1%, while the worst single day was May 12, 2017 at -62.0%.

Capricor Therapeutics, Inc. has an annualized alpha of 107.78%, beta of 0.63, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 14, 2007.

• This stock participated in 103.43% of S&P 500 Index downside but only 13.10% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.63 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CAPR ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Capricor Therapeutics, Inc. (CAPR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Capricor Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Capricor Therapeutics, Inc. was 99.97%, occurring on Mar 10, 2020. The portfolio has not yet recovered.

The current Capricor Therapeutics, Inc. drawdown is 99.06%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Capricor Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Capricor Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.